171 related articles for article (PubMed ID: 36694873)
1. Electrical storm in hypertrophic cardiomyopathy: Cardiac magnetic resonance and sudden cardiac death risk stratification: a case report.
Garcia Brás P; Rosa SA; Portugal G; Oliveira MM
Eur Heart J Case Rep; 2023 Jan; 7(1):ytad010. PubMed ID: 36694873
[TBL] [Abstract][Full Text] [Related]
2. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
[TBL] [Abstract][Full Text] [Related]
3. Refractory electrical storm in a patient with hypertrophic cardiomyopathy and an implantable cardioverter-defibrillator.
Nakayama H; Komatsu J; Nishimura Y; Sugane H; Hosoda H; Imai RI; Nakaoka Y; Nishida K; Mito S; Seki SI; Kubokawa SI; Fukatani M; Kawai K; Hamashige N; Doi Y
J Cardiol Cases; 2023 May; 27(5):233-236. PubMed ID: 37180214
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
[TBL] [Abstract][Full Text] [Related]
5. Solving the Riddle of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: The Added Role of Cardiac Magnetic Resonance.
Stankowski K; Figliozzi S; Lisi C; Catapano F; Panico C; Cannata F; Mantovani R; Frontera A; Bragato RM; Stefanini G; Monti L; Condorelli G; Francone M
J Cardiovasc Dev Dis; 2023 May; 10(6):. PubMed ID: 37367391
[TBL] [Abstract][Full Text] [Related]
6. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.
Rowin EJ; Maron BJ; Haas TS; Garberich RF; Wang W; Link MS; Maron MS
J Am Coll Cardiol; 2017 Feb; 69(7):761-773. PubMed ID: 28209216
[TBL] [Abstract][Full Text] [Related]
7. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
[TBL] [Abstract][Full Text] [Related]
8. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Ventricular Fibrosis on Cardiac Magnetic Resonance Imaging Associates With Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy.
McLELLAN AJ; Ellims AH; Prabhu S; Voskoboinik A; Iles LM; Hare JL; Kaye DM; Macciocca I; Mariani JA; Kalman JM; Taylor AJ; Kistler PM
J Cardiovasc Electrophysiol; 2016 May; 27(5):571-80. PubMed ID: 26840595
[TBL] [Abstract][Full Text] [Related]
10. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
[TBL] [Abstract][Full Text] [Related]
11. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
13. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience.
Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N
Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403
[TBL] [Abstract][Full Text] [Related]
14. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
[TBL] [Abstract][Full Text] [Related]
15. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
16. Management and outcomes of hypertrophic cardiomyopathy in young adults.
Baron É; Karam N; Donal E; Puscas T; Mirabel M; Bacher A; Wahbi K; Mazzella JM; Jeunemaitre X; Reant P; Hagège A;
Arch Cardiovasc Dis; 2021; 114(6-7):465-473. PubMed ID: 33744178
[TBL] [Abstract][Full Text] [Related]
17. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy.
Perazzolo Marra M; De Lazzari M; Zorzi A; Migliore F; Zilio F; Calore C; Vettor G; Tona F; Tarantini G; Cacciavillani L; Corbetti F; Giorgi B; Miotto D; Thiene G; Basso C; Iliceto S; Corrado D
Heart Rhythm; 2014 May; 11(5):856-63. PubMed ID: 24440822
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.
Hen Y; Tsugu-Yagawa M; Iguchi N; Utanohara Y; Takada K; Machida H; Takara A; Teraoka K; Inoue K; Takamisawa I; Takayama M; Yoshikawa T
Heart Vessels; 2018 Jan; 33(1):49-57. PubMed ID: 28766047
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics and Prognostic Importance of Left Ventricular Apical Aneurysms in Hypertrophic Cardiomyopathy.
Lee DZJ; Montazeri M; Bataiosu R; Hoss S; Adler A; Nguyen ET; Rakowski H; Chan RH
JACC Cardiovasc Imaging; 2022 Oct; 15(10):1696-1711. PubMed ID: 36202449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
